Omer Faruk Karatas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2576186/publications.pdf

Version: 2024-02-01

54 1,256 21 34
papers citations h-index g-inde

55

times ranked

g-index

2267

citing authors

55 all docs 55 docs citations

#	Article	IF	Citations
1	Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. Cellular Oncology (Dordrecht), 2016, 39, 187-193.	2.1	75
2	Overexpression of miR-145–5p Inhibits Proliferation of Prostate Cancer Cells and Reduces SOX2 Expression. Cancer Investigation, 2015, 33, 251-258.	0.6	73
3	Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. Journal of Gene Medicine, 2014, 16, 331-335.	1.4	72
4	miR-1 and miR-133b Are Differentially Expressed in Patients with Recurrent Prostate Cancer. PLoS ONE, 2014, 9, e98675.	1.1	70
5	Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clinical and Experimental Hypertension, 2015, 37, 643-649.	0.5	69
6	Interaction of gold nanoparticles with mitochondria. Colloids and Surfaces B: Biointerfaces, 2009, 71, 315-318.	2.5	65
7	The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncology, 2014, 10, 1027-1048.	1.1	57
8	MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications. Oral Oncology, 2017, 67, 124-130.	0.8	57
9	Differential Expression of Hypertension-Associated MicroRNAs in the Plasma of Patients With White Coat Hypertension. Medicine (United States), 2015, 94, e693.	0.4	50
10	The altered promoter methylation of oxytocin receptor gene in autism. Journal of Neurogenetics, 2016, 30, 280-284.	0.6	48
11	Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate, 2014, 74, 1498-1505.	1.2	46
12	Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. International Journal of Cancer, 2015, 136, 875-879.	2.3	42
13	Role of miR-145 in human laryngeal squamous cell carcinoma. Head and Neck, 2016, 38, 260-266.	0.9	40
14	miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer. Oncotarget, 2017, 8, 60243-60256.	0.8	34
15	The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells. Tumor Biology, 2016, 37, 4183-4192.	0.8	33
16	The role of ATPâ€binding cassette transporter genes in the progression of prostate cancer. Prostate, 2016, 76, 434-444.	1.2	29
17	RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Research, 2017, 77, 4247-4257.	0.4	28
18	MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. Laryngoscope, 2015, 125, E377-E381.	1.1	27

#	Article	IF	CITATIONS
19	Novel <i>POC1A</i> mutation in primordial dwarfism reveals new insights for centriole biogenesis. Human Molecular Genetics, 2015, 24, 5378-5387.	1.4	26
20	MicroRNAs as prognostic markers in prostate cancer. Prostate, 2019, 79, 265-271.	1.2	25
21	Gcm/Glide-dependent conversion into glia depends on neural stem cell age, but not on division, triggering a chromatin signature that is conserved in vertebrate glia. Development (Cambridge), 2011, 138, 4167-4178.	1.2	22
22	Alpha-B-crystallin expression in human laryngeal squamous cell carcinoma tissues. Head and Neck, 2015, 37, 1344-1348.	0.9	20
23	Antiproliferative potential of miRâ€33a in laryngeal cancer Hepâ€2 cells via targeting <i>PIM1</i> . Head and Neck, 2018, 40, 2455-2461.	0.9	20
24	Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. BMC Cancer, 2016, 16, 853.	1.1	18
25	Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens. Current Stem Cell Research and Therapy, 2014, 9, 347-353.	0.6	18
26	Interlocked loops trigger lineage specification and stable fates in the Drosophila nervous system. Nature Communications, 2014, 5, 4484.	5.8	16
27	Novel mutants of the aubergine gene. Fly, 2016, 10, 81-90.	0.9	16
28	Design, synthesis and biological evaluation of 3,5-diaryl isoxazole derivatives as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127427.	1.0	13
29	ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer. Cell Biology International, 2020, 44, 242-252.	1.4	11
30	Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells. Molecular Biology Reports, 2021, 48, 1393-1400.	1.0	11
31	CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. Prostate Cancer and Prostatic Diseases, 2021, 24, 891-902.	2.0	11
32	Revealing the functions of novel mutations in <i>RAB3GAP1</i> in Martsolf and Warburg micro syndromes. American Journal of Medical Genetics, Part A, 2019, 179, 579-587.	0.7	10
33	The roles of microRNAs in the stemness of oral cancer cells. Oral Oncology, 2020, 109, 104950.	0.8	10
34	The effects of <i>Daucus carota</i> extract against PC3, PNT1a prostate cells, acetylcholinesterase, glutathione Sâ€transferase, and αâ€glycosidase; an in vitroâ€"in silico study. Journal of Food Biochemistry, 2021, 45, e13975.	1.2	10
35	AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cellular Oncology (Dordrecht), 2022, 45, 41-56.	2.1	10
36	Mode of action of carboplatin via activating p53/miRâ€145 axis in head and neck cancers. Laryngoscope, 2020, 130, 2818-2824.	1.1	9

#	Article	IF	CITATIONS
37	Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells. Molecular Biology Reports, 2020, 47, 5431-5438.	1.0	8
38	MicroRNAâ€145 transcriptionally regulates Semaphorin 3A expression in prostate cancer cells. Cell Biology International, 2021, 45, 1082-1090.	1.4	7
39	Whole-exome sequencing revealed two novel mutations in Usher syndrome. Gene, 2015, 563, 215-218.	1.0	6
40	Low vitamin D and high cholesterol facilitate oral carcinogenesis in 4NQOâ€induced rat models via regulating glycolysis. Oral Diseases, 2023, 29, 978-989.	1.5	6
41	A novel EFNB1 mutation in a patient with craniofrontonasal syndrome and right hallux duplication. Gene, 2013, 527, 675-678.	1.0	5
42	MicroRNA profiling in lymphocytes and serum of tyrosinemia type-l patients. Molecular Biology Reports, 2013, 40, 4619-4623.	1.0	5
43	A novel frameshift mutation and infrequent clinical findings in two cases with Dyggve–Melchior–Clausen syndrome. Clinical Dysmorphology, 2014, 23, 1-7.	0.1	5
44	Characterization of stem-like cells in a new astroblastoma cell line. Experimental Cell Research, 2017, 352, 393-402.	1.2	5
45	MEX3D is an oncogenic driver in prostate cancer. Prostate, 2021, 81, 1202-1213.	1.2	5
46	Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN. Oncotarget, 2018, 9, 14456-14471.	0.8	5
47	Synthesis and biological evaluation of 3,5â€diarylâ€pyrazole derivatives as potential antiprostate cancer agents. Archiv Der Pharmazie, 2021, 354, e2100225.	2.1	4
48	Comprehensive in silico analysis for identification of novel candidate target genes, including DHX36, OPA1, and SENP2, located on chromosome 3q in head and neck cancers. Head and Neck, 2021, 43, 288-302.	0.9	3
49	MiR-33a and statins collaboratively reduce the proliferative capacity of prostate cancer cells. The European Research Journal, 0 , , .	0.1	1
50	Toward PCR-free mutation detection based on surface-enhanced Raman scattering. Proceedings of SPIE, 2009, , .	0.8	0
51	Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil. Clinical Cancer Drugs, 2020, 7, 16-24.	0.3	0
52	Perisentrik inv(12)(p11.2q14)'nin İnfertilite ve Tekrarlayan Düşüklerle İlişkisi: Vaka Örneği ve Lit Taraması. Duzce Universitesi Tip Fakültesi Dergisi, 0, , .	eratür 0.3	0
53	Could the "Stiff Rim Sign―Be an Indicator of Lysyl Oxidase Activity in Breast Cancer?. Iranian Journal of Radiology, 2019, 16, .	0.1	0
54	The AKT antagonist AZD5363 suppresses features associated with cancer progression in human larynx cancer cells. The European Research Journal, 0, , .	0.1	0